MedTrace Logo

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

NCT03954626 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to collect ECG data after a single IVT injection of brolucizumab 6 mg in patients with neovascular age-related macular degeneration (nAMD).

Conditions

  • Age-Related Macular Degeneration
  • Macular Degeneration
  • Wet Macular Degeneration
  • Retinal Degeneration
  • Retinal Diseases
  • Eye Diseases

Interventions

BIOLOGICAL

brolucuzumab 6 mg IVT

Single intravitreal injection (IVT) of brolucizumab 6 mg

Sponsors & Collaborators

Principal Investigators

  • Nadia Zakaria, MD · Novartis Institutes for BioMedical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-07
Primary Completion
2019-07-09
Completion
2019-07-31
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03954626 on ClinicalTrials.gov